Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab-govitecan in Metastatic Esophagogastric Adenocarcinoma
NCT06123468Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Apr 2024
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of sacituzumab govitecan in Esophago-Gastric Adenocarcinoma, sponsored by Institut für Klinische Krebsforschung. Started Apr 2024; status: completed.
02
Drugs
sacituzumab govitecan
03
Conditions
Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on NCT06123468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06123468.